

Neeta Pandit-Taskar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7923670/publications.pdf>

Version: 2024-02-01

93
papers

4,518
citations

109321

35
h-index

110387

64
g-index

95
all docs

95
docs citations

95
times ranked

5366
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. <i>Lancet Oncology</i> , The, 2007, 8, 304-310.	10.7	370
2	Sequential Cytarabine and ^{131}I -Particle Immunotherapy with Bismuth-213 α - ¹³¹ I-Intuzumab (HuM195) for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5303-5311.	7.0	234
3	Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 97, 409-418.	2.9	208
4	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	6.4	208
5	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase I trial. <i>Lancet Oncology</i> , The, 2018, 19, 1040-1050.	10.7	201
6	First-in-Humans Imaging with ⁸⁹ Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020, 61, 512-519.	5.0	170
7	A Phase I/II Study for Analytic Validation of ⁸⁹ Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	7.0	163
8	Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1358-65.	5.0	143
9	⁸⁹ Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2093-2105.	6.4	130
10	Radiation dosimetry of ¹⁸ F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. <i>BMC Medical Imaging</i> , 2016, 16, 41.	2.7	122
11	Pilot Trial of Unlabeled and Indium-111 α -Labeled Anti α -Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 7454-7461.	7.0	120
12	First-in-Human Imaging with ⁸⁹ Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	5.0	116
13	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	9.4	115
14	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹ Zr-Trastuzumab in Patients with Esophagogastric Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 161-166.	5.0	96
15	Biodistribution and Dosimetry of ¹⁸ F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. <i>Journal of Nuclear Medicine</i> , 2018, 59, 147-153.	5.0	96
16	Organ and fetal absorbed dose estimates from ^{99m} Tc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1202-8.	5.0	88
17	Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. <i>Gynecologic Oncology</i> , 2010, 117, 59-64.	1.4	85
18	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using ¹¹¹ In-J591: Lesion Detectability and Dosimetric Projections for ⁹⁰ Y Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1066-1074.	5.0	76

#	ARTICLE	IF	CITATIONS
19	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2707-2713.	7.0	73
20	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist ¹⁷⁷ Lu-Satoreotide Tetraxetan. <i>Clinical Cancer Research</i> , 2019, 25, 6939-6947.	7.0	69
21	Norepinephrine Transporter as a Target for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 39S-53S.	5.0	67
22	Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1697-1702.	5.0	64
23	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. <i>EJNMMI Research</i> , 2015, 5, 28.	2.5	63
24	Molecular Imaging of Biomarkers in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 53S-59S.	5.0	56
25	Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET. <i>American Journal of Roentgenology</i> , 2004, 183, 1143-1147.	2.2	54
26	I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 203-214.	4.6	52
27	CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹ Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262485.	5.0	49
28	¹²⁴ I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1878-1885.	5.0	47
29	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7014-7023.	7.0	47
30	A phase II study of radioimmunotherapy with intraventricular ¹³¹ I- β F8 for medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26754.	1.5	46
31	Biodistribution and radiation dose estimates for ⁶⁸ Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 677-685.	6.4	44
32	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	2.8	42
33	High-Specific-Activity- ¹³¹ I-MIBG versus ¹⁷⁷ Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	7.0	42
34	Oncologic imaging in gynecologic malignancies. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1842-50.	5.0	42
35	Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. <i>Clinical Colorectal Cancer</i> , 2015, 14, 296-305.	2.3	40
36	A comparison of pediatric and adult CT organ dose estimation methods. <i>BMC Medical Imaging</i> , 2017, 17, 28.	2.7	40

#	ARTICLE	IF	CITATIONS
37	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4283-4291.	1.6	40
38	⁸⁹ Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1825-1832.	5.0	38
39	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹ Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1517-1523.	5.0	38
40	Transient sialoadenitis: A complication of ¹³¹ I- metaiodobenzylguanidine therapy. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1271-1273.	1.5	36
41	Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. <i>Seminars in Hematology</i> , 2018, 55, 22-32.	3.4	31
42	Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using ⁹⁰ Y-Loaded Resin Microspheres. <i>American Journal of Roentgenology</i> , 2016, 207, 661-670.	2.2	29
43	Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴ I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1794-1801.	5.0	29
44	Patient-specific organ and effective dose estimates in pediatric oncology computed tomography. <i>Physica Medica</i> , 2018, 45, 146-155.	0.7	27
45	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (²²⁵ Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 768-768.	1.4	27
46	Pharmacokinetics and Biodistribution of a [⁸⁹ Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Molecular Pharmaceutics</i> , 2019, 16, 3083-3090.	4.6	26
47	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2642-2651.	6.4	26
48	Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 245-249.	2.9	22
49	PET Imaging of Breast Cancer. <i>PET Clinics</i> , 2015, 10, 159-195.	3.0	21
50	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [⁶⁴ Cu]Cu-NOTA-anti-CD8 PET. <i>Clinical Cancer Research</i> , 2021, 27, 1958-1966.	7.0	21
51	Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. <i>Clinical Cancer Research</i> , 2022, 28, 2030-2037.	7.0	21
52	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2300-2309.	6.4	20
53	Comparison of ⁶⁸ Ga-DOTA-JR11 PET/CT with dosimetric ¹⁷⁷ Lu-satoreotide tetraxetan (¹⁷⁷ Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3047-3057.	6.4	19
54	Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. <i>Journal of Nuclear Medicine</i> , 2021, 62, 60S-72S.	5.0	19

#	ARTICLE	IF	CITATIONS
55	Targeted Radioimmunotherapy and Theranostics with Alpha Emitters. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S41-S44.	0.3	18
56	Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 744-751.	1.1	18
57	Feasibility of Administering High-Dose ¹³¹ I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms. <i>Pediatric Blood and Cancer</i> , 2016, 63, 801-807.	1.5	17
58	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹ I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 231-237.	5.0	17
59	Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy. <i>Clinical Nuclear Medicine</i> , 2017, 42, 741-748.	1.3	17
60	I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. <i>EJNMMI Research</i> , 2018, 8, 20.	2.5	17
61	Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. <i>Journal of Neuro-Oncology</i> , 2019, 143, 101-106.	2.9	17
62	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Targeted Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 73S-78S.	5.0	16
63	ImmunoPET: harnessing antibodies for imaging immune cells. <i>Molecular Imaging and Biology</i> , 2022, 24, 181-197.	2.6	15
64	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2007, 110, 910-910.	1.4	15
65	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 12S-22S.	5.0	14
66	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1700-1706.	6.4	13
67	A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 913-922.	0.8	12
68	Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML). <i>Blood</i> , 2004, 104, 1790-1790.	1.4	12
69	Molecular Immune Targeted Imaging of Tumor Microenvironment. <i>Nanotheranostics</i> , 2022, 6, 286-305.	5.2	11
70	Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26549.	1.5	10
71	Patient-adapted organ absorbed dose and effective dose estimates in pediatric 18F-FDG positron emission tomography/computed tomography studies. <i>BMC Medical Imaging</i> , 2020, 20, 9.	2.7	10
72	Long Half-Life ⁸⁹ Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 399-402.	5.0	9

#	ARTICLE	IF	CITATIONS
73	IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamabâ€”pharmacokinetic modeling to optimize therapeutic index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1166-1177.	6.4	9
74	Novel Agents and Future Perspectives on Theranostics. <i>Seminars in Radiation Oncology</i> , 2021, 31, 83-92.	2.2	9
75	FDG PET/CT imaging features and clinical utility in COVID-19. <i>Clinical Imaging</i> , 2021, 80, 262-267.	1.5	8
76	Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 31-31.	1.6	8
77	New strategies in radioimmunotherapy for lymphoma. <i>Current Oncology Reports</i> , 2003, 5, 364-371.	4.0	7
78	F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3179-3188.	2.1	7
79	The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by 111Indium-labeled humanized monoclonal antibody 3S193. <i>European Journal of Radiology</i> , 2008, 67, 292-299.	2.6	6
80	Restaging [18F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 878-886.	1.2	6
81	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 125-137.	4.1	5
82	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1836-1843.	5.0	5
83	Immune-Directed Molecular Imaging Biomarkers. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 584-603.	4.6	3
84	Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 662-664.	5.0	3
85	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 447-456.	1.9	3
86	Acute myeloid leukemia therapy elicits durable complete response in chemoradioâ€”resistant metastatic paraganglioma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26314.	1.5	2
87	Radiation Safety Considerations and Clinical Advantages of Î±-Emitting Therapy Radionuclides. <i>Journal of Nuclear Medicine Technology</i> , 2022, 50, 10-16.	0.8	2
88	Biodistribution and Radiation Dosimetry of Intraperitoneally Administered ¹²⁴ I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1094-1100.	5.0	2
89	The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature. <i>American Journal of Roentgenology</i> , 2017, 209, 182-186.	2.2	1
90	Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4810-4810.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device. Journal of Neuro-Oncology, 2022, 157, 457-463.	2.9	1
92	Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.. Blood, 2004, 104, 5113-5113.	1.4	0
93	Imaging in malignant adrenal cancers. , 2022, , .		0